In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Fate Therapeutics (FATE), with a price target of $27. The company’s shares closed last Monday at $16.95.
According to TipRanks.com, Goldstein has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.4% and a 32.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Merck & Company, and Xencor Inc.
Fate Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $27.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.82 and a one-year low of $11. Currently, Fate Therapeutics has an average volume of 717.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
